SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced the appointment of Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Romano, who is based in the United States, brings more than two decades of finance leadership experience in the medical technology and life sciences sectors. She will help lead the company’s financial operations as it advances its global expansion strategy, including the pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations. Her track record of capital raising and financial stewardship is expected to be instrumental as SSII navigates the regulatory and commercialization phases of its growth.
The appointment comes at a critical time for SS Innovations, which is focused on making robotic surgery more affordable and accessible globally. The company’s SSi Mantra system and SSi Mudra surgical instruments support a variety of procedures, including cardiac surgery. With Romano’s expertise, the company aims to strengthen its balance sheet and accelerate its path to FDA clearance, a key milestone for entering the U.S. market. For more details, the full press release is available at https://ibn.fm/pAqlP.
SS Innovations, an American company headquartered in India, plans to expand the global presence of its cost-effective surgical robotic solutions. The appointment of Romano underscores the company’s commitment to financial discipline and strategic growth as it prepares for potential market expansion. The company’s forward-looking statements, as outlined in its SEC filings, highlight risks and uncertainties that could affect actual results, and investors are advised to review these disclosures before making investment decisions. Further information about the company and its disclaimers can be found at http://IBN.fm/Disclaimer.
